0001764974false00017649742024-06-032024-06-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 03, 2024

 

 

Turnstone Biologics Corp.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41747

83-2909368

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

9310 Athena Circle, Suite 300

 

La Jolla, California

 

92037

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (347) 897-5988

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock ($0.001 par value)

 

TSBX

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Turnstone Biologics Corp. (the ''Company'') held its Annual Meeting of Stockholders on June 3, 2024 (the "Annual Meeting") . The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth in the following tables. Each of these proposals is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2024.

 

Proposal No.1 - To elect three nominees for Class I directors, to hold office until the 2027 Annual Meeting of Stockholders and his or her successor has been duly elected and qualified or, if sooner, until such director’s earlier death, resignation or removal. The votes were cast as follows:

 

 

Name

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

Broker
Non-Votes

 

Michael Burgess, MBChb, Ph.D.

 

 

13,700,490

 

 

 

-

 

 

 

130,618

 

 

 

894,978

 

Robert Gould, Ph.D.

 

 

11,212,703

 

 

 

-

 

 

 

2,618,405

 

 

 

894,978

 

Rishi Gupta

 

 

13,768,277

 

 

 

-

 

 

 

62,831

 

 

 

894,978

 

 

Proposal No.2 - To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. The votes were cast as follows:

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

Broker
Non-Votes

 

 

14,713,502

 

 

 

11,884

 

 

 

700

 

 

 

-

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TURNSTONE BIOLOGICS CORP.

Date: June 5, 2024

By:

/s/ Sammy Farah

Sammy Farah, M.B.A., Ph.D.

President and Chief Executive Officer and Director

 


v3.24.1.1.u2
Document And Entity Information
Jun. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 03, 2024
Entity Registrant Name Turnstone Biologics Corp.
Entity Central Index Key 0001764974
Entity Emerging Growth Company true
Entity File Number 001-41747
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-2909368
Entity Address, Address Line One 9310 Athena Circle, Suite 300
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (347)
Local Phone Number 897-5988
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock ($0.001 par value)
Trading Symbol TSBX
Security Exchange Name NASDAQ

Turnstone Biologics (NASDAQ:TSBX)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Turnstone Biologics Charts.
Turnstone Biologics (NASDAQ:TSBX)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Turnstone Biologics Charts.